Arcus Biosciences (RCUS) PT Lowered to $40 at Citi
Tweet
Share
E-mailGet Alerts RCUS Hot Sheet
Price: $29.08 -4.18%
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Arcus Biosciences (NYSE: RCUS) to $40.00 (from $42.00) while maintaining a Buy rating.
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Edgewise Therapeutics (EWTX) PT Raised to $60 at JPMorgan
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
